A Blockbuster Opportunity
Kalydeco Combo Surprises with Lung Function Benefit
By Catherine Shaffer
Tuesday, May 8, 2012
Cystic fibrosis patients received welcome good news Monday, as Vertex Pharmaceuticals Inc. reported that its ongoing Phase II trial of VX-809 and Kalydeco (ivacaftor) showed significant lung function improvements in an interim analysis of patients homozygous for the F508del mutation.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.